s22-9198_8k.htm
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): May 15, 2009
ADEONA
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
1-12584
|
|
13-3808303
|
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File No.)
|
|
(IRS
Employer Identification
No.)
|
3930
Varsity Drive, Ann Arbor, Michigan 48106
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (734) 332-7800
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
2.02. Results
of Operations and Financial Condition
On May 15, 2009, Adeona Pharmaceuticals
Inc. released its financial results for the quarter ended March 31,
2009. A copy of the Company’s press release is attached hereto as
Exhibit 99.1 and is hereby incorporated by reference (the “Press
Release”).
The
information provided in the response to this Item 2.02 and the accompanying
Exhibit 99.1 are being furnished under Item 2.02 of Form 8-K and shall not be
deemed to be “filed” for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, or otherwise subject to the liability of such Section,
nor shall such information be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, regardless of
any general incorporation by reference language in any such filing, except as
shall be expressly set forth by specific reference in such filing.
Item
9.01. Financial
Statements and Exhibits
(d) Exhibits. The
following exhibits are being furnished as part of this Report.
|
Exhibit
Number
|
Description
|
|
|
|
|
99.1
|
Press
release regarding earnings issued by Adeona Pharmaceuticals Inc. dated May
15, 2009
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
ADEONA
PHARMACEUTICALS INC. |
| Date: May 15,
2009 |
By: /s/ Steve H.
Kanzer |
| |
Name:
Steve H. Kanzer |
| |
Its:
Chief Executive Officer |
|
Exhibit
Number
|
Description
|
|
|
|
|
99.1
|
Press
release regarding earning issued by Adeona Pharmaceuticals Inc. dated May
15, 2009
|